




RealRate

PHARMACEUTICAL 2022

Korro Bio Inc
Rank 251 of 471

FREQUENCY
THERAPEUTICS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Korro Bio Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Korro Bio Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Korro Bio Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 4.8% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	134,748
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,429
Liabilities, Non-Current	28,938
Other Assets	45,088
Other Compr. Net Income	-89
Other Expenses	1,045
Other Liabilities	14,167
Other Net Income	390
Other Revenues	14,068
Property and Equipment	5,522
Research and Development	60,923
Selling, General and Administrative Expense	37,176

Output Variable	Value in 1000 USD
Assets	185,358
Liabilities	54,534
Expenses	99,144
Revenues	14,068
Stockholders Equity	130,824
Net Income	-84,686
Comprehensive Net Income	-84,730
BaseVar	176,792
ECR before Limited Liability	167%
Economic Capital Ratio	280%